<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01880320</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.18240</org_study_id>
    <nct_id>NCT01880320</nct_id>
  </id_info>
  <brief_title>Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel-group Vehicle and Active Controlled Study to Compare the Efficacy and Safety of CD0271 0.3% / CD1579 2.5% Topical Gel Versus Topical Gel Vehicle in Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis are based on the assumption that :

        -  CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical
           Gel Vehicle in the overall population and in the subgroup of severe Subjects

        -  CD0271 0.3%/CD1579 2.5% Gel applied once daily for up to 12 weeks has an acceptable
           safety and tolerability profile
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success Rate</measure>
    <time_frame>Week 12</time_frame>
    <description>Success was defined as 'Clear' or 'Almost Clear' on the Investigator Global Assessment (IGA).
Success rate at Week 12 was estimated using multiple imputation approach which is an average of response from multiple imputed datasets.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes From Baseline in Inflammatory Lesion Counts</measure>
    <time_frame>Baseline - Week12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes From Baseline in Non-Inflammatory Lesion Counts</measure>
    <time_frame>Baseline - Week 12</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">503</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>CD0271 0.3% /CD1579 2.5% Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD0271 0.1% / CD1579 2.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Gel Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD0271 0.3% / CD1579 2.5%</intervention_name>
    <arm_group_label>CD0271 0.3% /CD1579 2.5% Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD0271 0.1% / CD1579 2.5%</intervention_name>
    <arm_group_label>CD0271 0.1% / CD1579 2.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Gel Vehicle</intervention_name>
    <arm_group_label>Topical Gel Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, who is 12 years of age or older at Screening visit.

          2. Clinical diagnosis of acne vulgaris with facial involvement.

          3. An IGA of Moderate (3) or Severe (4) at Baseline visit.

          4. A minimum of 20 but not more than 100 inflammatory lesions (papules and pustules) on
             the face (including the nose) at Baseline visit.

          5. A minimum of 30 but not more than 150 non-inflammatory lesions (open comedones and
             closed comedones) on the face (including the nose) at Baseline visit.

        Exclusion Criteria:

          1. More than 2 acne nodules on the face at Baseline visit.

          2. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.),
             nodulo cystic acne, or acne requiring systemic treatment.

          3. Underlying diseases or other dermatologic conditions that require the use of
             interfering topical or systemic therapy or that might interfere with study assessments
             such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea. This
             includes clinically significant abnormal findings, uncontrolled or serious disease, or
             any medical or surgical condition, that may either interfere with the interpretation
             of the clinical trial results, and/or put the subject at significant risk (according
             to Investigator's judgment) if he/she participates in the clinical trial.

          4. The subject has received, applied or taken some specified treatments within the
             specified timeframe prior to the Baseline visit

          5. The subject is unwilling to refrain from use of prohibited medication during the
             clinical trial.

          6. Use of hormonal contraceptives solely for control of acne.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Galderma Investigational site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigationnal Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investiogational Site</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>New-York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Barrie</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Markham</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investiogational Site</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Peterborough</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational site</name>
      <address>
        <city>Surrey</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2013</study_first_posted>
  <results_first_submitted>March 7, 2016</results_first_submitted>
  <results_first_submitted_qc>July 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2016</results_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CD0271 0.3% /CD1579 2.5% Gel</title>
          <description>Active arm
CD0271 0.3% / CD1579 2.5%</description>
        </group>
        <group group_id="P2">
          <title>CD0271 0.1% / CD1579 2.5%</title>
          <description>Comparator arm
CD0271 0.1% / CD1579 2.5%</description>
        </group>
        <group group_id="P3">
          <title>Topical Gel Vehicle</title>
          <description>Placebo arm
Topical Gel Vehicle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="217"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="192"/>
                <participants group_id="P3" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CD0271 0.3% /CD1579 2.5% Gel</title>
          <description>Active arm
CD0271 0.3% / CD1579 2.5%</description>
        </group>
        <group group_id="B2">
          <title>CD0271 0.1% / CD1579 2.5%</title>
          <description>Comparator arm
CD0271 0.1% / CD1579 2.5%</description>
        </group>
        <group group_id="B3">
          <title>Topical Gel Vehicle</title>
          <description>Placebo arm
Topical Gel Vehicle</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="217"/>
            <count group_id="B2" value="217"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="503"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.1" spread="7.59"/>
                    <measurement group_id="B2" value="19.4" spread="6.75"/>
                    <measurement group_id="B3" value="18.5" spread="5.72"/>
                    <measurement group_id="B4" value="19.6" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Investigator Global Assessment (IGA)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Baseline IGA = Moderate (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline IGA = Severe (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success Rate</title>
        <description>Success was defined as 'Clear' or 'Almost Clear' on the Investigator Global Assessment (IGA).
Success rate at Week 12 was estimated using multiple imputation approach which is an average of response from multiple imputed datasets.</description>
        <time_frame>Week 12</time_frame>
        <population>Intent-to-treat (ITT): All subjects who were randomized. Baseline IGA Severe population: All randomized subjects who had IGA=4 at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>CD0271 0.3% /CD1579 2.5% Gel</title>
            <description>Active arm
CD0271 0.3% / CD1579 2.5%</description>
          </group>
          <group group_id="O2">
            <title>CD0271 0.1% / CD1579 2.5%</title>
            <description>Comparator arm
CD0271 0.1% / CD1579 2.5%</description>
          </group>
          <group group_id="O3">
            <title>Topical Gel Vehicle</title>
            <description>Placebo arm
Topical Gel Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate</title>
          <description>Success was defined as 'Clear' or 'Almost Clear' on the Investigator Global Assessment (IGA).
Success rate at Week 12 was estimated using multiple imputation approach which is an average of response from multiple imputed datasets.</description>
          <population>Intent-to-treat (ITT): All subjects who were randomized. Baseline IGA Severe population: All randomized subjects who had IGA=4 at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All subjects (MI: Multiple Imputation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline IGA=Severe (4) (MI: Multiple Imputation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                    <measurement group_id="O2" value="20.5"/>
                    <measurement group_id="O3" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline in Inflammatory Lesion Counts</title>
        <time_frame>Baseline - Week12</time_frame>
        <population>ITT Population, Multiple imputation</population>
        <group_list>
          <group group_id="O1">
            <title>CD0271 0.3% /CD1579 2.5% Gel</title>
            <description>Active arm
CD0271 0.3% / CD1579 2.5%</description>
          </group>
          <group group_id="O2">
            <title>CD0271 0.1% / CD1579 2.5%</title>
            <description>Comparator arm
CD0271 0.1% / CD1579 2.5%</description>
          </group>
          <group group_id="O3">
            <title>Topical Gel Vehicle</title>
            <description>Placebo arm
Topical Gel Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Inflammatory Lesion Counts</title>
          <population>ITT Population, Multiple imputation</population>
          <units>Lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.04" spread="0.846"/>
                    <measurement group_id="O2" value="-26.72" spread="0.822"/>
                    <measurement group_id="O3" value="-14.40" spread="1.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline IGA = Severe (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.17" spread="1.407"/>
                    <measurement group_id="O2" value="-31.92" spread="1.320"/>
                    <measurement group_id="O3" value="-15.46" spread="2.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline in Non-Inflammatory Lesion Counts</title>
        <time_frame>Baseline - Week 12</time_frame>
        <population>ITT Population, Multiple Imputation</population>
        <group_list>
          <group group_id="O1">
            <title>CD0271 0.3% /CD1579 2.5% Gel</title>
            <description>Active arm
CD0271 0.3% / CD1579 2.5%</description>
          </group>
          <group group_id="O2">
            <title>CD0271 0.1% / CD1579 2.5%</title>
            <description>Comparator arm
CD0271 0.1% / CD1579 2.5%</description>
          </group>
          <group group_id="O3">
            <title>Topical Gel Vehicle</title>
            <description>Placebo arm
Topical Gel Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Non-Inflammatory Lesion Counts</title>
          <population>ITT Population, Multiple Imputation</population>
          <units>lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.18" spread="1.332"/>
                    <measurement group_id="O2" value="-39.00" spread="1.277"/>
                    <measurement group_id="O3" value="-18.47" spread="2.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline IGA = Severe (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.61" spread="2.058"/>
                    <measurement group_id="O2" value="-43.10" spread="1.847"/>
                    <measurement group_id="O3" value="-17.25" spread="3.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CD0271 0.3% /CD1579 2.5% Gel</title>
          <description>Active arm
CD0271 0.3% / CD1579 2.5%</description>
        </group>
        <group group_id="E2">
          <title>CD0271 0.1% / CD1579 2.5%</title>
          <description>Comparator arm
CD0271 0.1% / CD1579 2.5%</description>
        </group>
        <group group_id="E3">
          <title>Topical Gel Vehicle</title>
          <description>Placebo arm
Topical Gel Vehicle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized Anxiety Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Infleunza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Rhinitis seasonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Galderma CPM</name_or_title>
      <organization>Galderma R&amp;D</organization>
      <phone>00 33 4 93 95 70 70</phone>
      <email>clinicaltrials@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

